Randomized Trial of Stopping or Continuing ART among Postpartum Women with Pre-ART CD4 \( \geq 400 \) cells/mm\(^3\) (PROMISE 1077HS)

J Currier, P Britto, R Hoffman, S Brummel, G Masheto, E Joao, B Santos, L Aurnipibul, M Losso, MF Pierre, A Weinberg, N Chakhtoura, R Browning, A Coletti, D Shapiro, and J Pilotto for the 1077HS Team
Background

• The health benefits of antiretroviral therapy (ART) for women in the postpartum period with high CD4 cell counts have not been evaluated in randomized trials.

• The aim of our study was to assess the risks and benefits of continued ART vs stopping ART among non-breastfeeding women after delivery.
Study Design: Randomized Trial

• Key Eligibility
  – HIV-infected postpartum women
  – No clinical indication for ART based on local guidelines
  – CD4 cell count 400 cells/mm³ or higher (prior to ART and at delivery)
  – ART naïve except for PMTCT
  – Received ART for PMTCT during current pregnancy (at least 4 weeks)
  – Not breastfeeding or planning to breastfeed

• Study Follow-up
  – Participants were randomized to continue or stop ART within 42 days of delivery; those who stopped were restarted when CD4 dropped below 350 cells/mm³ or when clinically indicated
  – Participants were seen 4 weeks after enrollment and every 12 weeks thereafter through 84 weeks after the last enrollment.
  – ART was provided by the study (Lopinavir/r +TDF/FTC preferred regimen)
Study Design: Endpoints

• **Primary Composite Endpoint:**
  – Time to AIDS event (WHO Stage 4 Condition), serious cardiovascular, renal, hepatic event or death

• **Primary Safety Endpoint:**
  – Time to first targeted Grade 2, Grade 3 or 4 event

• **Key Secondary Endpoints:**
  – Composite endpoint of HIV/AIDS-related event or WHO Clinical Stage 2 or 3 event
  – Time to WHO Clinical Stage 2 or 3 events
Study Design: Sample Size and Monitoring

• Sample size of 2000 participants provided 90% power to detect a 50% reduction from an annualized primary event rate of 2.07%
• Intent-to-treat analysis included all women randomized
• Comparisons between treatment groups based on log rank tests and Cox regression models for estimation of treatment effect sizes
• Enrollment from January 2010-November 2014
• November 2014 - DSMB approved curtailing enrollment at 1,630 participants
• Analyses reflect follow-up until July 7, 2015
  – Participants were informed about the START results and all were offered ART
Study Sites

52 clinical research sites in 8 countries

- Argentina
- Botswana
- Brazil
- China
- Haiti
- Peru
- Thailand
- US
1917 Screened

1653 Enrolled

CONTINUE ART
(median = 2.31 years)
79 (9.6%) premature d/c
15% d/c ART

STOP ART
(median = 2.35 years)
70 (8.5%) premature d/c
12% restarted ART prior to study threshold

70 (8.5%) premature d/c
12% restarted ART prior to study threshold

Study Sites

USA (29) 9%
Argentina (1) 3%
Botswana (2) 28%
Brazil (8) 31%
Thailand (7) 18%
Peru (2) 1%
Haiti (1) 4%
China (1) 6%
## Baseline Characteristics

<table>
<thead>
<tr>
<th></th>
<th>CONTINUE ART n=827</th>
<th>STOP ART n=825</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median age</td>
<td>27 years</td>
<td>28 years</td>
</tr>
<tr>
<td>Median Screening CD4</td>
<td>696 cells/mm³</td>
<td>695 cells/mm³</td>
</tr>
<tr>
<td>Median Pre-ART CD4</td>
<td>550 cells/mm³</td>
<td>548 cells/mm³</td>
</tr>
<tr>
<td>WHO Stage 1</td>
<td>98%</td>
<td>99%</td>
</tr>
<tr>
<td>HIV-1 RNA &lt;400</td>
<td>91%</td>
<td>91%</td>
</tr>
<tr>
<td>PMTCT ART</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PI-based</td>
<td>77%</td>
<td>76%</td>
</tr>
<tr>
<td>NNRTI-based</td>
<td>22%</td>
<td>21%</td>
</tr>
<tr>
<td>On Study ART</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LPV/r based</td>
<td>74%</td>
<td>NA</td>
</tr>
<tr>
<td>ATV/r based</td>
<td>19%</td>
<td></td>
</tr>
</tbody>
</table>
During F/U 31% of Stop arm started ART at median CD4 372 cells/mm$^3$
AIDS-defining event, serious non-AIDS event, or death due to any cause

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Continue ART</th>
<th>Stop ART</th>
<th>Hazard Ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary Efficacy Composite Endpoint</td>
<td>4</td>
<td>6</td>
<td>0.68 (0.19, 2.40)</td>
</tr>
<tr>
<td>AIDS Defining Event</td>
<td>2</td>
<td>3</td>
<td>0.67 (0.11, 4.02)</td>
</tr>
<tr>
<td>Serious Non-AIDS Event</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Death</td>
<td>2</td>
<td>4</td>
<td>0.52 (0.09, 2.81)</td>
</tr>
</tbody>
</table>

Logrank p = 0.54
Primary Efficacy Outcome

AIDS-defining event, serious non-AIDS event, or death due to any cause

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Continue ART</th>
<th>Stop ART</th>
<th>Hazard Ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary Efficacy Composite Endpoint</td>
<td>4</td>
<td>6</td>
<td>0.68 (0.19, 2.40)</td>
</tr>
<tr>
<td>AIDS Defining Event</td>
<td>2</td>
<td>3</td>
<td>0.67 (0.11, 4.02)</td>
</tr>
<tr>
<td>Serious Non-AIDS Event</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Death</td>
<td>2</td>
<td>4</td>
<td>0.52 (0.09, 2.81)</td>
</tr>
</tbody>
</table>

Clinical Endpoints

Continue
- 2 cervical cancer
- 2 deaths, homicide (1), unknown (1)

Stop
- 2 extrapulm TB
- 1 Toxo
- 4 deaths: TB (1), hepatic encep (1), unknown (2)
**Primary Safety Endpoint**

*Composite of time to first Grade 3 or 4 sign or symptom or Grade 2, 3 or 4 chemistry or hematology result*

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Continue ART</th>
<th>Stop ART</th>
</tr>
</thead>
<tbody>
<tr>
<td>No</td>
<td>Rate per 100 py</td>
<td>No</td>
</tr>
<tr>
<td>Primary Safety Composite Endpoint</td>
<td>260</td>
<td>18.4 (15.7, 21.4)</td>
</tr>
</tbody>
</table>
### Time to WHO Clinical Stage 2 or 3 Condition

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Continue ART</th>
<th>Stop ART</th>
<th>Hazard Ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Composite of HIV/AIDS Related Event or WHO Stage 2 or 3 Event</td>
<td>No: 57</td>
<td>3.09</td>
<td>No: 99</td>
</tr>
<tr>
<td>WHO Stage 2 or 3 Event</td>
<td>39</td>
<td>2.02</td>
<td>80</td>
</tr>
</tbody>
</table>
### Time to WHO Clinical Stage 2 or 3 Condition

<table>
<thead>
<tr>
<th>Key WHO 2/3 conditions</th>
<th>Continue (39)</th>
<th>Stop (80)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulm TB</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>Herpes Zoster</td>
<td>16</td>
<td>43</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td>Oral Candidiasis</td>
<td>0</td>
<td>10</td>
</tr>
<tr>
<td>Bacterial Infections</td>
<td>4</td>
<td>11</td>
</tr>
</tbody>
</table>

#### Composite of HIV/AIDS Related Event or WHO Stage 2 or 3 Event

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Continue ART</th>
<th>Stop ART</th>
<th>Hazard Ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Composite of HIV/AIDS Related Event or WHO Stage 2 or 3 Event</td>
<td>57</td>
<td>99</td>
<td>0.56 (0.41, 0.78)</td>
</tr>
<tr>
<td>WHO Stage 2 or 3 Event</td>
<td>39</td>
<td>80</td>
<td>0.47 (0.32, 0.68)</td>
</tr>
</tbody>
</table>
Virologic Failure (VF) and Resistance

- **VF:** Confirmed HIV-1 RNA > 1000 copies/ml at or after 24 weeks of ART
  - Among the 827 initially randomized to continue ART:
    - 76 (9%) experienced a single VL > 1000 copies/ml and re-suppressed
    - 15 had single VL > 1000 copies/ml and were lost to F/U
    - **189 (23%) experienced confirmed VF**

- Resistance Testing
  - Available for 155 (82%) of those with VF:
    - 103 (66%) had no evidence of resistance at the time of failure*
    - Among the 52 with evidence of resistance
      - 22 had resistance to one of the drugs in the failing regimen
      - 11% (14/125) failing PI regimen
      - 30% (8/27) failing NNRTI regimen

*Note: overall 90% of participants were on PI based ART
Summary

• ART was safe and well-tolerated among post-partum women with CD4 cell counts ≥ 400

• Rates of AIDS defining and serious non-AIDS events were lower than expected and did not differ significantly by randomized arm
  – Rates of WHO Stage 2 and 3 events were halved with continued ART

• Virologic failure occurred in 23%, reflecting challenges with adherence in this population
Conclusions

• The safety and clinical benefit of continued ART observed in this randomized trial supports the use of continued ART (Option B+) for postpartum women

• Interventions to improve adherence as well as studies to examine newer regimens with a high genetic barrier to resistance are needed to insure maximal long term benefit.
Protocol Team and Site Investigators

The 1077 PROMISE study team gratefully acknowledges the dedication and commitment of the 1652 participants without whom this study would not have been possible.

Protocol Chairs and Clinical Management Committee
  J Currier, J Pilotto, R Hoffman

Operations Center
  A Coletti, K McCarthy

Statistical and Data Management Center
  M Basar, P Britto, S Brummel, A Gonzalez,
  L Marillo, A Manzella, D Shapiro, A Zadzilka
  * Steve Lagakos

Laboratory Center:  A Loftis, S Fiscus

Field Representatives:  N Sublette, M Toye

Community Advisory Board Representative:  M Giwa

Sponsors:
  US NIH: R Browning, D Gnanashanmugam, K Klingman,
  L Purdue, N Chakhtoura, L Mofenson, G Siberry, H
  Watts, * Ed Handelsman
  AbbVie: J Van Wyk
  Bristol-Myers Squibb: K Misar, A Villasis
  Gilead Sciences: J Rooney
  GlaxoSmithKline/ViiV:  W Snowden ; Merck and
  Company:  R Leavitt

Endpoint Review Group:  H Watts, K Godfrey, B Coombs,
  J Anderson

Site Investigators of Record

Argentina  Botswana
  M Losso  G Masheto

Brazil
  E Machado, J de Menezes, J Pinto, G Duarte,
  R Sperhalcke, J Pilotto, R Kreitchman, B Santos

China  Haiti
  L Wei  J Pape

Peru
  J Sanchez, E Sandoval

Thailand
  K Chokephaibulkit, J Achalapong, G Halue,
  P Yuthavisuthi, S Prommas, C Bowonwatanuwong,
  V Sirisanthana

United States
  S Riddler, P Kumar, W Shearer, R Yogev, G Scott,
  S Spector, C Cunningham, M Bamji, E Cooper,
  A Wiznia, J Hitti, P Emmanuel, R Scott, M Acevedo,
  S Nachman, T Jones, S Rana,  M Keller, A Stek,
  M Rathore, E McFarland, A Puga, A Agwu, T Chen,
  R Van Dyke, J Deville, M Purswani, P Tebas, P Flynn,
  M Fischl

* In Memoriam
Overall support for the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network was provided by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) under Award Numbers UM1AI068632 (IMPAACT LOC), UM1AI068616 (IMPAACT SDMC) and UM1AI106716 (IMPAACT LC), with co-funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Institute of Mental Health (NIMH).

Overall support for the AIDS Clinical Trials Group (ACTG) 5UM1AI068636

The content of this presentation is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Antiretroviral drugs were provided free of charge for this study by AbbVie, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline/ViiV, and Merck and Company.